Strategic Partnerships for Fc-Engager Development

LoopLab Bio is advancing a first-in-class Fc-Engager platform, designed to promote durable, antigen-specific immune tolerance without broad immunosuppression.

We are actively seeking strategic partnerships with pharma and biotech companies to accelerate the development of this technology through:

• Co-development of lead assets from discovery to clinical stage

• Licensing opportunities for indication-specific applications

• Strategic alliances to combine Fc-Engager technology with partner pipelines (enzymes, antibodies, or cell/gene therapies)

Partnership areas of focus:

• Autoimmune & allergy

• Rare metabolic disorders / ADA prevention

• Transplant tolerance

• Emerging areas

Our robust IP position, validated preclinical systems, and experienced leadership team provide a strong foundation for collaboration. We look forward to building long-term, balanced partnerships that bring durable immune tolerance therapies to patients worldwide.